Eosinophilic Pneumonia: Diagnosis and Management
Executive Summary
1. Classification, Epidemiology, and Pathophysiology
Eosinophilic pneumonias represent a spectrum of disorders unified by abnormal eosinophil accumulation in the pulmonary parenchyma. The Allen and Davis classification divides eosinophilic lung diseases into idiopathic forms (acute eosinophilic pneumonia, chronic eosinophilic pneumonia, idiopathic hypereosinophilic syndrome) and secondary forms (parasitic infection, drug-induced, ABPA, eosinophilic granulomatosis with polyangiitis). The two idiopathic forms differ markedly in onset, demographics, and natural history but share an exquisite responsiveness to corticosteroids.
Eosinophil Biology in the Lung
Eosinophils are normally rare in healthy alveoli (less than 1 percent of BAL cells). Their recruitment requires IL-5 (the dominant eosinophilopoietin and survival factor), eotaxins (CCL11, CCL24, CCL26), and adhesion molecules including VCAM-1 and Siglec-8. Once activated, eosinophils degranulate releasing major basic protein, eosinophil cationic protein, eosinophil-derived neurotoxin, and eosinophil peroxidase — all directly cytotoxic to airway epithelium and capable of triggering airway hyperreactivity. The IL-5 axis is the therapeutic target of mepolizumab (anti-IL-5), reslizumab (anti-IL-5), and benralizumab (anti-IL-5Rα) — all approved for severe eosinophilic asthma and increasingly used off-label in steroid-dependent CEP and EGPA.
Acute Eosinophilic Pneumonia (AEP) — Epidemiology
- Mean age 20-40 years; M:F = 2:1
- Smoking initiation or resumption within 1 month is the primary trigger (military deployment, dust exposure, e-cigarette/vaping)
- Reported clusters in US military deployed to Iraq/Afghanistan (sandstorm + smoking)
- EVALI (e-cigarette/vaping-associated lung injury) overlaps clinically and pathologically with AEP
- Drugs: daptomycin (most reported), nitrofurantoin, NSAIDs, minocycline, sulfasalazine, infliximab
Chronic Eosinophilic Pneumonia (CEP) — Epidemiology
- Mean age 45-65 years; F:M = 2:1 (reverse of AEP)
- Asthma history present in 50 percent (often coexisting; nasal polyps in 30 percent)
- Atopic background in two-thirds; non-smokers predominate
- Reported associations: prior radiation therapy (breast cancer), inhaled allergen exposure
- Drug triggers similar to AEP but onset over weeks to months
2. Clinical Presentation and Diagnostic Workup
AEP vs CEP — Comparative Clinical Features
| Feature | Acute Eosinophilic Pneumonia (AEP) | Chronic Eosinophilic Pneumonia (CEP) |
|---|---|---|
| Onset | Days to 1-2 weeks (rapidly progressive) | Weeks to months (insidious) |
| Demographics | Young adults (20-40), male predominance | Middle-aged (45-65), female predominance |
| Smoking history | Recent initiation/resumption (1 month) | Non-smokers predominate |
| Asthma history | Uncommon | 50 percent |
| Symptoms | High fever, severe dyspnea, cough, chest pain | Low-grade fever, cough, dyspnea, weight loss, night sweats |
| Respiratory failure | 50-70 percent require ICU; ARDS-like | Rare; outpatient-manageable |
| Peripheral blood eosinophils | Often NORMAL at presentation (rises after recovery) | Elevated >1000/μL in 90 percent |
| BAL eosinophils | >25 percent (often 30-60 percent) | >25 percent (often 25-90 percent) |
| HRCT pattern | Bilateral diffuse infiltrates, ground-glass, septal thickening, pleural effusions (50 percent) | Peripheral non-segmental upper lobe infiltrates (“photographic negative of pulmonary edema”) |
| Steroid response | Dramatic, within 24-48h | Within 48-72h |
| Relapse rate | <5 percent | 50-80 percent during taper |
Diagnostic Criteria for AEP (Philit Criteria)
- Acute febrile illness less than 1 month duration
- Bilateral diffuse infiltrates on chest imaging
- PaO2 less than 60 mmHg on room air OR SaO2 less than 90 percent OR PaO2/FiO2 less than 300
- BAL eosinophils greater than 25 percent OR lung biopsy with eosinophilic pneumonia
- No infection (negative cultures, viral PCR, parasite serology)
- No drug exposure or other known cause of eosinophilic lung disease
- Prompt and complete response to corticosteroids without relapse
Bronchoscopy and BAL Technique
BAL is the gold-standard diagnostic test. Flexible bronchoscopy with lavage of right middle lobe or lingula (or area of greatest radiographic abnormality) using 100-150 mL sterile saline in 20-50 mL aliquots. Recovery of 30-70 percent is acceptable. Studies to send routinely:
- Cell count and differential (target: BAL eosinophils greater than 25 percent for diagnosis)
- Gram stain, bacterial culture (aerobic + anaerobic + quantitative)
- AFB stain and mycobacterial culture
- Fungal stain (KOH, GMS) and culture
- PCP DFA or PCR
- Galactomannan (Aspergillus)
- Viral PCR panel (influenza, RSV, COVID, CMV, HSV)
- Cytology (atypical cells, malignancy)
- Strongyloides serology if any travel history or immunocompromise
Lung biopsy (transbronchial or surgical) is rarely needed when BAL eosinophilia plus characteristic clinical/radiographic features are present. It is required when EGPA (vasculitis confirmation), atypical infection, or alternative diagnosis is suspected.
HRCT Patterns
| Pattern | AEP | CEP |
|---|---|---|
| Distribution | Bilateral, diffuse, no zonal predominance | Peripheral, subpleural, upper lobe predominance |
| Density | Ground-glass + consolidation, smooth septal thickening | Patchy consolidation, ground-glass |
| Pleural effusions | 50 percent (bilateral, exudative with eosinophils) | Uncommon |
| Lymphadenopathy | Mediastinal nodes 30 percent | Uncommon |
| Migrating infiltrates | Less common | Hallmark feature (different lobes over weeks if untreated) |
3. Differential Diagnosis and Mandatory Exclusions
Five Categories That Must Be Systematically Excluded
| Category | Specific Causes | Workup |
|---|---|---|
| Parasitic infections | Strongyloides stercoralis (Loffler), Ascaris, hookworm, Toxocara, Schistosoma, Paragonimus, filariasis | Stool ova/parasites × 3, Strongyloides serology (IgG ELISA), Toxocara serology, Schistosoma serology if travel history; treat empirically with ivermectin 200 mcg/kg PO if suspected before steroids |
| Drug-induced | Daptomycin (top reported), NSAIDs, nitrofurantoin, sulfonamides, minocycline, phenytoin, carbamazepine, infliximab, mesalamine, amiodarone (over 100 drugs implicated) | Detailed drug history within 6 weeks; check pneumotox.com database; resolution after drug withdrawal supports diagnosis |
| ABPA | Aspergillus fumigatus colonization in asthmatics | Total IgE greater than 1000 IU/mL, Aspergillus-specific IgE/IgG, eosinophilia greater than 500/μL, central bronchiectasis on HRCT, mucus plugs |
| EGPA (Churg-Strauss) | Asthma + eosinophilia + vasculitis triad | ANCA (MPO-ANCA in 40 percent), mononeuritis multiplex, sinusitis, eosinophilic infiltrates with vasculitis on biopsy; meet 4/6 ACR criteria |
| Hypereosinophilic syndrome (HES) | Idiopathic vs FIP1L1-PDGFRA mutation (myeloid) vs lymphocytic (clonal T-cells) | Eosinophilia greater than 1500/μL for greater than 6 months with end-organ damage; FISH for FIP1L1-PDGFRA, T-cell flow cytometry, tryptase |
Strongyloides — The Universal Treat-Before-Steroids Concern
Drug-Induced Eosinophilic Pneumonia — Top Offenders
| Drug | Typical Onset | Notes |
|---|---|---|
| Daptomycin | 2-4 weeks of therapy | Most common cause of drug-induced AEP; FDA boxed warning; check CK and BAL eos in any daptomycin patient with respiratory symptoms |
| Nitrofurantoin | Days (acute) to months (chronic) | Both AEP and CEP patterns; common cause in elderly with UTI prophylaxis |
| NSAIDs (especially diclofenac) | Days to weeks | Cross-reactivity within NSAID class |
| Minocycline | Days to 3 weeks | Common in young adults treated for acne; DRESS syndrome overlap |
| Sulfasalazine, sulfa antibiotics | Variable | Stevens-Johnson and DRESS risk too |
| Amiodarone | Months to years | Eosinophilic pneumonia is one of several pulmonary toxicity patterns |
| Anti-TNF agents (infliximab, etanercept) | Weeks to months | Reported with all biologics |
4. Corticosteroid Therapy and Drug Doses
Acute Eosinophilic Pneumonia (AEP) — Treatment
| Setting | Regimen | Duration |
|---|---|---|
| ARDS / mechanical ventilation | Methylprednisolone 60-125 mg IV q6h until extubation OR PaO2/FiO2 >300 | Until clinical stabilization (typically 2-7 days) |
| Severe but no ICU | Methylprednisolone 60 mg IV q6h × 3-5 days, transition to PO | Then transition |
| Transition to oral | Prednisone 40-60 mg PO daily | 2-4 weeks at full dose |
| Taper | Decrease prednisone by 10 mg every 1-2 weeks | Total duration 4 weeks |
Smoking cessation is mandatory after AEP — recurrence rate after smoking resumption is high.
Chronic Eosinophilic Pneumonia (CEP) — Treatment
| Phase | Regimen | Duration |
|---|---|---|
| Induction | Prednisone 0.5 mg/kg/day PO (typically 40-60 mg PO daily) | 2 weeks until clinical/radiographic response |
| Consolidation | Prednisone 0.25 mg/kg/day PO (20-30 mg) | 2-4 weeks |
| Taper | Decrease by 5-10 mg every 2 weeks | Target total 6-12 months |
| Maintenance (if relapsing) | Prednisone 5-15 mg PO daily lowest dose to control symptoms; OR inhaled corticosteroids high-dose | Often years |
| Steroid-sparing (relapsing/severe) | Mepolizumab 100 mg SC q4 weeks (anti-IL-5) | Indefinite |
Up to 80 percent of CEP patients relapse during steroid taper, typically when prednisone falls below 10-15 mg/day. Many require chronic low-dose maintenance corticosteroids for years. Monitor for steroid toxicity: weight, BP, glucose, bone density (DEXA every 1-2 years), cataracts.
Adjunctive Care
- PCP prophylaxis: TMP-SMX SS (80/400 mg) PO daily if prednisone ≥20 mg/day for >1 month
- Bone protection: Calcium 1200 mg + Vitamin D 800-1000 IU daily; bisphosphonate if expected duration >3 months at >7.5 mg prednisone
- PPI: Omeprazole 20 mg PO daily for steroid gastritis prevention
- Vaccines: Pneumococcal (PCV15/20 + PPSV23), annual influenza, RSV (age ≥60), COVID-19 boosters; AVOID live vaccines while on prednisone >20 mg/day
- Diabetes screening: A1c at baseline and 3 months; fasting glucose if symptomatic
- Asthma optimization: Inhaled corticosteroid (high-dose fluticasone 500 mcg BID or equivalent) + LABA in CEP patients with asthma to reduce systemic steroid requirement
5. Steroid-Sparing Agents and Specialist Referral
Anti-IL-5 Biologics for Steroid-Refractory or Relapsing CEP
| Drug | Mechanism | Dose | Evidence in EP |
|---|---|---|---|
| Mepolizumab (Nucala) | Anti-IL-5 | 100 mg SC q4 weeks | Best evidence; reduces relapses, allows steroid reduction; FDA-approved for severe asthma, EGPA, HES; off-label CEP |
| Reslizumab (Cinqair) | Anti-IL-5 | 3 mg/kg IV q4 weeks | Less data in CEP; weight-based |
| Benralizumab (Fasenra) | Anti-IL-5Rα (depletes eosinophils via ADCC) | 30 mg SC q8 weeks | Off-label CEP; rapid eosinophil depletion |
| Dupilumab (Dupixent) | Anti-IL-4Rα | 300 mg SC q2 weeks | Less direct effect on eosinophils; consider for asthma comorbidity |
Other Steroid-Sparing Approaches
- High-dose inhaled corticosteroids: Fluticasone 500-1000 mcg BID or equivalent; reduces oral prednisone requirement
- Azathioprine: 2-3 mg/kg/day PO; check TPMT first; modest evidence in EGPA but limited CEP data
- Mycophenolate mofetil: 1-1.5 g PO BID; case reports in steroid-dependent CEP
- Cyclophosphamide: Reserved for EGPA with vasculitis or organ-threatening disease
- IVIG: 2 g/kg over 2-5 days, q4-6 weeks; case reports in refractory disease
When to Refer
- All AEP cases: Pulmonary referral mandatory; ICU admission for hypoxemic respiratory failure (typically required in 50-70 percent).
- Suspected ABPA, EGPA, HES: Pulmonology + Allergy/Immunology or Rheumatology — these conditions have specific diagnostic criteria and treatment regimens.
- Steroid-dependent or relapsing CEP: Pulmonology center with biologic experience for mepolizumab/benralizumab initiation.
- Atypical features: Hemoptysis, cavitation, persistent fever despite steroids, or atypical imaging — exclude vasculitis, infection, malignancy.
- Failure to respond within 72 hours: Reconsider diagnosis; rebronchoscopy with biopsy.
- Drug-induced cases: Consultation with Allergy if multiple drugs; report to FDA MedWatch.
7. Practice Insights: Bedside Notes on Eosinophilic Pneumonia
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Peripheral eosinophilia with pulmonary infiltrates narrows nothing on its own, since drugs, parasites, and EGPA produce the same picture, which is why this disease’s diagnostic pitfall is the differential rather than the recognition. In experienced hands the pivot points are taking forensic drug history before steroid commitment, screening for parasitic infection (Strongyloides) before immunosuppression, and recognizing EGPA features that change therapy from steroids alone to steroids + biologic. Seasoned clinicians track three things every visit: peripheral eosinophil count trajectory, BAL eosinophil percentage at diagnosis, and 6-minute walk distance during taper.
What the Guideline Misses — Strongyloides Screen Before Steroids
Strongyloides hyperinfection from steroid immunosuppression is catastrophic. In experienced practice every eosinophilic pneumonia patient gets Strongyloides serology (IgG ELISA) before starting prednisone, especially if any tropical/subtropical exposure history, immigrant background, or rural farming. Empiric ivermectin 200 mcg/kg PO once if serology is pending or risk is high. About 1 in 12 of such patients had positive Strongyloides serology — would have been disastrous to start steroids without screening.
Patterns That Repeat in Practice — Drug-Induced Mimics
Nitrofurantoin, daptomycin, NSAIDs, sulfa drugs, minocycline, mesalamine. In practice experienced practitioners do a forensic medication review listing every drug started in the prior 6 months. About 1 in 4 of the “idiopathic CEP” referrals turn out to be drug-induced after careful history — the cure is drug withdrawal, sometimes without long-term steroids needed. Daptomycin pneumonitis is the fastest-growing drug-induced eosinophilic pneumonia experienced clinicians see in inpatients.
EGPA Screen on Every CEP
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) overlaps with CEP — asthma + eosinophilia + organ involvement (cardiac, neuro, renal, skin). In practice every CEP patient gets ANCA testing (MPO predominant), urinalysis, BNP, EKG, nerve conduction studies if any neurologic complaint. About 1 in 6 of the CEP workups reveal EGPA features that change management to mepolizumab + steroids vs steroids alone.
Bedside Heuristic — AEP Responds in 24-72 Hours
Acute eosinophilic pneumonia responds dramatically to steroids — most patients off ICU support within 72 hours of methylprednisolone 60-125 mg IV q6h. Failure to improve in 72 hours mandates reconsidering diagnosis (drug toxicity not yet withdrawn, infection, vasculitis). Smoking initiation in young patients is the classic AEP trigger; clinicians consistently ask about cigarette or vaping start in recent weeks.
A Case That Reframed The Approach — Strongyloides Hyperinfection Averted
A man in his late 40s, immigrant from Southeast Asia 15 years prior, presented with subacute dyspnea and peripheral infiltrates on CXR. BAL showed 65% eosinophils. Diagnosis: chronic eosinophilic pneumonia. Before starting prednisone 60 mg, the treating clinicians sent Strongyloides IgG and treated empirically with ivermectin 200 mcg/kg PO × 2 doses 14 days apart. Serology came back positive. He completed ivermectin without complication, then steroids over 8 months with full resolution. What clinicians learned: any immigrant or rural-exposure patient with eosinophilia who needs steroids gets empiric ivermectin first. The 24-hour drug treatment may have saved his life — Strongyloides hyperinfection in steroid-treated patients has 70-90% mortality.
Practice Pattern Refinements That Diverge From Standard Guidelines
- Strongyloides serology + empiric ivermectin in high-risk patients before steroids. The 24-hour ivermectin treatment is trivial; hyperinfection is fatal. Seasoned clinicians do not wait for serology in high-risk patients (immigrant, tropical, immunocompromised, rural).
- Forensic 6-month drug history before steroid commitment. Nitrofurantoin, daptomycin, NSAIDs, sulfa, minocycline, mesalamine, antiseizure drugs — list every drug. Drug-induced eosinophilic pneumonia resolves with drug withdrawal in maybe 1 in 4 referrals; lifelong steroids would have been overtreatment.
- EGPA screen (ANCA + UA + cardiac workup) on every CEP, not just “classical” presentations. Cardiac involvement is the leading cause of EGPA mortality. Catch it before it manifests. Mepolizumab 300 mg SC q4 weeks added to prednisone reduces relapses meaningfully in EGPA.
- Slow taper over 6-12 months in CEP, not 3 months. CEP relapse rate is 50-80% with rapid taper. Experienced practitioners extend taper to 6-12 months, reducing prednisone by 5 mg every 2-4 weeks. About half the CEP patients still relapse during slower tapers — those add mepolizumab as steroid-sparing.
6. Surveillance, Relapse Management, and FAQ
Long-Term Surveillance
| Time Point | Assessment |
|---|---|
| Baseline (before steroid) | HRCT, PFTs (FEV1, FVC, DLCO), CBC with diff, total IgE, ANCA, baseline DEXA if expected long course, A1c, LFTs |
| 2 weeks | Clinical assessment, CXR (should show marked improvement), CBC for eosinophil response |
| 1 month | HRCT (resolution of infiltrates), PFTs (recovery of DLCO) |
| 3, 6, 12 months | PFTs, CXR, monitor for relapse during taper; A1c if on chronic steroids |
| Relapse triggers | Recurrent cough, dyspnea, peripheral eosinophilia >500/μL, new infiltrates → resume induction prednisone dose |
| Long-term (CEP) | DEXA every 1-2 years on chronic steroids; cataract eye exam annually; monitor for adrenal insufficiency on prolonged taper |
Relapse Management for CEP
- Confirm relapse with imaging (recurrent infiltrates) and/or BAL eosinophilia
- Exclude alternative diagnosis (especially infection during immunosuppression)
- Resume induction-dose prednisone 0.5 mg/kg/day until response
- Slower taper than initial course (every 4 weeks instead of 2)
- If 2 or more relapses: initiate steroid-sparing (mepolizumab or high-dose ICS)
- Consider chronic maintenance prednisone 5-10 mg if frequent relapses
Frequently Asked Questions
Primary guideline documents this article draws on. Links resolve via DOI to the publisher; access may require a subscription.
- ATS/IDSA 2019 Guideline: Community-acquired Pneumonia in Adults (American Journal of Respiratory and Critical Care Medicine · 2019)